Table 2.
Baseline atherothrombotic risk factors categorized by BMI
| Risk factors | BMI <25 N = 216 |
25–29.9 N = 776 |
30–34.9 N = 733 |
35–39.9 N = 347 |
≥40 N = 202 |
P value |
|---|---|---|---|---|---|---|
| HDL-cholesterola (mg/dl) | 40 ± 11 | 39 ± 10 | 38 ± 10 | 37 ± 9 | 39 ± 11 | 0.014 |
| Triglyceridesb (mg/dl) | 137 (95, 197) | 144 (103, 210) | 156 (105, 224) | 159 (118, 235) | 152 (101, 228) | <0.001 |
| LDL-cholesterola (mg/dl) | 98 ± 37 | 97 ± 34 | 95 ± 31 | 95 ± 33 | 102 ± 36 | 0.11 |
| Systolic BPa (mm Hg) | 129 ± 21 | 131 ± 20 | 133 ± 20 | 134 ± 20 | 131 ± 19 | 0.05 |
| Diastolic BPa (mm Hg) | 74 ± 11 | 74 ± 11 | 75 ± 12 | 75 ± 12 | 74 ± 12 | 0.35 |
| Urine AC ratiob (mg/g) | 12 (5, 63) | 11 (5, 34) | 13 (5, 49) | 14 (5, 70) | 17 (6, 63) | 0.02 |
| HbA1ca (%) | 7.9 ± 1.8 | 7.6 ± 1.6 | 7.6 ± 1.6 | 7.7 ± 1.6 | 7.6 ± 1.6 | 0.24 |
| Insulinb (muU/ml) | 6 (3, 12) | 8 (5, 13) | 11 (7, 19) | 13 (8, 21) | 14 (8, 23) | <0.001 |
| PAI-1 activityb (au/ml) | 12 (8, 19) | 14 (9, 23) | 16 (10, 27) | 22 (13, 31) | 20 (12, 29) | <0.001 |
| PAI-1 antigenb (ng/ml) | 19 (12, 27) | 21 (14, 32) | 23 (15, 34) | 27 (17, 40) | 28 (18, 40) | <0.001 |
| CRPb (ug/ml) | 1 (1, 4) | 2 (1, 4) | 2 (1, 6) | 4 (2, 8) | 6 (3, 10) | <0.001 |
| Fibrinogena (mg/dl) | 358 ± 88 | 354 ± 95 | 362 ± 98 | 388 ± 95 | 399 ± 103 | <0.001 |
| D-dimerb (ug/ml) | 0.35 (0.19, 0.69) | 0.30 (0.18, 0.59) | 0.30 (0.18, 0.55) | 0.32 (0.20, 0.59) | 0.35 (0.20, 0.69) | 0.11 |
BP, blood pressure; AC ratio, urinary albumin/creatinine ratio; PAI-1, plasminogen-activator inhibitor 1; CRP: C-reactive protein.
a
Data are shown as mean ± s.d. and a F-test was performed to test the differences of means among the BMI categories.
b
Due to the skewness of distribution, data are shown as median (first quartile, third quartile) and the Kruskal–Wallis test was performed to test the difference of Wilcoxon rank score among the BMI categories.